{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:14Z","timestamp":1785131954323,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030831","name":"Novartis Pharma K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030831","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Following asciminib\u2019s initial approval in Japan for chronic myeloid leukemia (CML) resistant or intolerant to previous therapy, this all-patient, postmarketing surveillance study was initiated. Predefined safety specifications, overall safety, and effectiveness were assessed for 48\u00a0weeks from asciminib initiation (safety analysis set, n\u2009=\u2009523). The approved daily dose of asciminib (80\u00a0mg [40\u00a0mg twice daily]) was most frequently used (63.9%) and not exceeded. Discontinuations (28.5%) were primarily due to adverse events (18.2%), including disease progression. Incidences of the safety specifications myelosuppression, pancreatitis, QT interval prolongation, infections, vascular occlusive events, and photosensitivity were 8.6%, 4.4%, 2.5%, 1.3%, 0.2%, and 0%, respectively, with low rates of treatment discontinuation for these events. There were no notable trends in the rates or types of adverse drug reactions in patients aged\u2009\u2265\u200965\u00a0years or with concurrent renal impairment, hepatic impairment, or cardiac dysfunction. The cumulative major molecular response rate was 61.2% by week 48 and was not affected by age (\u2265\u200965\u00a0years) or comorbidities. Cumulative MR\n                    <jats:sup>4.0<\/jats:sup>\n                    and MR\n                    <jats:sup>4.5<\/jats:sup>\n                    rates by week 48 were 42.3% and 26.5%, respectively, with some patients harboring baseline\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    mutations showing these responses. These real-world outcomes support the safety and effectiveness of asciminib for patients with resistant\/intolerant CML.\n                  <\/jats:p>","DOI":"10.1007\/s12185-026-04199-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:17:09Z","timestamp":1774984629000},"page":"177-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Postmarketing surveillance study of asciminib in patients with resistant\/intolerant chronic myeloid leukemia in Japan"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0494-7335","authenticated-orcid":false,"given":"Kazuaki","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Osako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"4199_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","volume":"90","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90:1440\u201354.","journal-title":"Mayo Clin Proc"},{"key":"4199_CR2","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.3390\/ijms25063307","volume":"25","author":"A Wu","year":"2024","unstructured":"Wu A, Liu X, Fruhstorfer C, Jiang X. Clinical insights into structure, regulation, and targeting of ABL kinases in human leukemia. Int J Mol Sci. 2024;25:3307.","journal-title":"Int J Mol Sci"},{"key":"4199_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"4199_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-022-03446-1","volume":"117","author":"Z Narl\u0131 \u00d6zdemir","year":"2023","unstructured":"Narl\u0131 \u00d6zdemir Z, K\u0131l\u0131\u00e7aslan NA, Y\u0131lmaz M, E\u015fkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities. Int J Hematol. 2023;117:3\u201315.","journal-title":"Int J Hematol"},{"key":"4199_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12185-024-03865-2","volume":"121","author":"N Takahashi","year":"2025","unstructured":"Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121:5\u201338.","journal-title":"Int J Hematol"},{"key":"4199_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","journal-title":"Leuk Res"},{"key":"4199_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733\u20137.","journal-title":"Nature"},{"key":"4199_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031\u201341.","journal-title":"Blood"},{"key":"4199_CR9","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1002\/cam4.5212","volume":"12","author":"J Yuda","year":"2023","unstructured":"Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib vs bosutinib in CML patients pretreated with \u22652 tyrosine kinase inhibitors: results from the Japanese subgroup analysis of ASCEMBL study. Cancer Med. 2023;12:2990\u20138.","journal-title":"Cancer Med"},{"key":"4199_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, R\u00e9a D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37:617\u201326.","journal-title":"Leukemia"},{"key":"4199_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12185-024-03805-0","volume":"120","author":"Y Minami","year":"2024","unstructured":"Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in patients with CML-CP previously treated with\u2009\u2265\u20092 tyrosine kinase inhibitors: 96-week results from the Japanese subgroup analysis of the ASCEMBL study. Int J Hematol. 2024;120:305\u201313.","journal-title":"Int J Hematol"},{"key":"4199_CR12","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1182\/bloodadvances.2025016042","volume":"9","author":"MM Mauro","year":"2025","unstructured":"Mauro MM, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, et al. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Adv. 2025;9:4248\u201359.","journal-title":"Blood Adv"},{"key":"4199_CR13","unstructured":"Novartis Europharm Limited. Scemblix 40 mg film-coated tablets\u2014summary of product characteristics (SmPC). 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/scemblix. Accessed 31 Jul 2025."},{"key":"4199_CR14","unstructured":"Novartis Pharmaceuticals Corp East Hanover, NJ. Scemblix [prescribing information]. 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/scemblix.pdf. Accessed 31 Jul 2025."},{"key":"4199_CR15","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381:2315\u201326.","journal-title":"N Engl J Med"},{"key":"4199_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400858","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391:885\u201398.\u00a0","journal-title":"N Engl J Med"},{"key":"4199_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04014-z","author":"N Takahashi","year":"2025","unstructured":"Takahashi N, Kikushige Y, Nakamae H, Goto T, Tomita A, Ichii M, et al. Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST. Int J Hematol. 2025;122:647\u201359.","journal-title":"Int J Hematol"},{"key":"4199_CR18","unstructured":"Pharmaceuticals and Medical Devices Agency. Antineoplastic agents\/tyrosine kinase inhibitors (ABL myristoyl pocket binding inhibitor) asciminib hydrochloride tablets 2025. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/300242_4291077F1027_1_05. Accessed 12 Aug 2025."},{"key":"4199_CR19","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10147-025-02811-4","volume":"30","author":"N Matsumura","year":"2025","unstructured":"Matsumura N, Mandai M. PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of belantamab mafodotin for multiple myeloma, asciminib for leukemia, osimertinib for lung cancer, amivantamab for lung cancer, and pembrolizumab for pleural mesothelioma in Japan. Int J Clin Oncol. 2025;30:1437\u20138.","journal-title":"Int J Clin Oncol"},{"key":"4199_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"4199_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2016;2016:170\u20139.","journal-title":"Hematology"},{"key":"4199_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"J Cortes","year":"2021","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.","journal-title":"J Hematol Oncol"},{"key":"4199_CR23","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1002\/cam4.3071","volume":"9","author":"M Breccia","year":"2020","unstructured":"Breccia M, Olimpieri PP, Olimpieri O, Pane F, Iurlo A, Foggi P, et al. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA). Cancer Med. 2020;9:4160\u20135.","journal-title":"Cancer Med"},{"key":"4199_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","volume":"94","author":"R Hehlmann","year":"2019","unstructured":"Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94:46\u201354.","journal-title":"Am J Hematol"},{"key":"4199_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000362816","volume":"87","author":"D Cella","year":"2014","unstructured":"Cella D, Nowinski CJ, Frankfurt O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology. 2014;87:133\u201347.","journal-title":"Oncology"},{"key":"4199_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110847","volume":"124","author":"F Cheng","year":"2023","unstructured":"Cheng F, Cui Z, Li Q, Wang L, Li W. Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia. Int Immunopharmacol. 2023;124:110847.","journal-title":"Int Immunopharmacol"},{"key":"4199_CR27","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"4199_CR28","volume-title":"Hematologic tumor treatment guidelines. Practical guidelines for hematological malignancies (revised version 2020)","author":"The Japanese Society of Hematology","year":"2018","unstructured":"The Japanese Society of Hematology. Hematologic tumor treatment guidelines. Practical guidelines for hematological malignancies (revised version 2020). Tokyo: Kanehara Publishing; 2018."},{"key":"4199_CR29","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1182\/blood-2024-200017","volume":"144","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, le Coutre P, Milojkovic D, Kim D, Lim S, Pavlovsky C, et al. Asciminib shows high efficacy and favorable tolerability at 80 mg once daily and 40 mg twice daily in patients with chronic phase chronic myelogenous leukemia previously treated with 2 or more tyrosine kinase inhibitors: primary analysis from the ASC4OPT study. Blood. 2024;144:4526\u20137.","journal-title":"Blood"},{"key":"4199_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","volume":"63","author":"FP Combes","year":"2024","unstructured":"Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, et al. Dose justification for asciminib in patients with philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet. 2024;63:1301\u201312.","journal-title":"Clin Pharmacokinet"},{"key":"4199_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107374","volume":"133","author":"FM Khadadah","year":"2023","unstructured":"Khadadah FM, Cerquozzi S, Olney HJ, Fraga C, Dudebout J, Xenocostas A, et al. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leuk Res. 2023;133:107374.","journal-title":"Leuk Res"},{"key":"4199_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3324\/haematol.2022.281386","volume":"108","author":"CCB Kockerols","year":"2023","unstructured":"Kockerols CCB, Janssen J, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY, et al. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population. Haematologica. 2023;108:240\u20134.","journal-title":"Haematologica"},{"key":"4199_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041045","volume":"15","author":"L P\u00e9rez-Lamas","year":"2023","unstructured":"P\u00e9rez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, P\u00e9rez L\u00f3pez R, et al. Toxicity of asciminib in real clinical practice: analysis of side effects and cross-toxicity with tyrosine kinase inhibitors. Cancers (Basel). 2023;15:1045.","journal-title":"Cancers (Basel)"},{"key":"4199_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clml.2024.09.013","volume":"25","author":"EL Atallah","year":"2025","unstructured":"Atallah EL, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, et al. Real-world evaluation of treatment patterns and clinical outcomes among patients with chronic myeloid leukemia in chronic phase treated with asciminib in clinical practice in the United States. Clin Lymphoma Myeloma Leuk. 2025;25:178\u201387.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4199_CR35","unstructured":"Pharmaceuticals and Medical Devices Agency. Review report. Scemblix tablets. https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220330001\/300242000_30400AMX00189_A100_1.pdf. Accessed 10 Nov 2025."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04199-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:35Z","timestamp":1785128675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4199"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04199-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kazuaki Yamaguchi is an employee of and owns stock in Novartis Pharma K.K. Makoto Aoki, and Ryohei Osako are employees of Novartis Pharma K.K.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}